- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02149654
Engager Align Post-market Clinical Study
The Engager ALIGN Study. To Characterize the Safety and Clinical Benefit of the Engager Transcatheter Aortic Valve Implantation System in a Real World Environment.
Purpose To characterize the safety and clinical benefit of the Engager Transcatheter Aortic Valve Implantation System in a real world environment.
Design Prospective non-randomized, non-interventional, multicenter, single-arm, post-market study.
250 Patients will have the Engager bioprosthesis implanted. Patients will be followed at 1 month, 6 months, and 12 months after the procedure. The recruitment period will be approximately 12 months, so the total study duration will be 24 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study objective is to characterize the safety and clinical benefit of the Engager Transcatheter Aortic Valve Implantation System in a real world setting.
The primary endpoint of this study is all-cause mortality at 30 days or during index hospitalization.
Secondary endpoints of this study are:
- Device success according to VARC2 is defined as:
- absence of procedural mortality (all-cause mortality at discharge, 30 days or during index hospitalization), AND
- correct positioning of the Engager bioprosthesis in the proper anatomic location, AND
- Engager bioprosthesis performing as intended (no prosthesis-patient mismatch and mean aortic valve gradient < 20 mmHg or peak velocity < 3 m/s, AND no moderate or severe regurgitation).
- Composite early safety (at 30 days) according to VARC2 includes the following components:
- all-cause mortality
- all stroke
- life-threatening bleeding
- acute kidney injury (stage 2-3)
- coronary artery obstruction requiring intervention
- major vascular complication
- valve-related dysfunction requiring repeat procedure (BAV, TAVI or SAVR)
- Clinical efficacy according to VARC2 at 6 months and 1 year is defined as:
- all-cause mortality
- all stroke
- hospitalizations for valve-related symptoms or worsening congestive heart failure (CHF)
- NYHA class III or IV
- valve-related dysfunction (mean aortic valve gradient ≥20 mm Hg, effective orifice area (EOA) ≤0.9-1.1 cm² and/or Doppler velocity index (DVI) <0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)
- Time-related valve safety accordingly to VARC2 at 6 months and 1 year is defined as:
- Structural valve deterioration
- Valve-related dysfunction (mean aortic valve gradient ≥20 mm Hg, (EOA) ≤0.9-1.1 cm² and/or (DVI) <0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)
- Requiring repeat procedure (TAVI or SAVR)
- Prosthetic valve endocarditis
- Prosthetic valve thrombosis
- Thrombo-embolic events (e.g. stroke)
VARC bleeding, unless clearly unrelated to valve therapy (e.g. trauma)
- All-cause mortality at 6 months and 1 year
- Cardiovascular mortality at 30 days, 6 months and 1 year
- Incidence of TAVI-related complications at 30 days, 6 months and 1 year:
- Myocardial infarction
- Periprocedural and spontaneous stroke
- Life-threatening, major and minor bleedings
- Acute kidney injury state 1, 2 and 3
- Apical and vascular complications
- Conduction disturbances
- Conversion to open-heart surgery
- Unplanned use of cardiopulmonary bypass
- Coronary obstruction and dissection
- Ventricular septal perforation
- Mitral valve apparatus damage or dysfunction
- Cardiac tamponade
- Endocarditis
- Valve thrombus
- Valve migration, embolization or ectopic valve deployment
Valve in valve deployment
- Total, transvalvular and paravalvular regurgitation as measured by TTE at 30 days and 1 year
- Mean aortic valve gradient, peak velocity and effective orifice area as measured by TTE at 30 days and 1 year
- Engager implant depth as measured by standard of care angiography at the end of implant procedure
- Incidence and rationale for permanent pacemaker implantation after Engager implant procedure
- Changes in Quality of Life as measured by the EQ5D questionnaire at baseline, discharge, 30 days, 6 months and 1 year
- Length of stay during index hospitalization (ICU and general ward)
- Incidence of re-hospitalization at 30 days, 6 months and 1 year
Subject population All patients with severe aortic stenosis requiring treatment, who are selected by a heart team to be treated electively with the Engager Transcatheter Aortic Valve Implantation System are eligible to be included in this study.
Treatment The Engager Transcatheter Aortic Bioprosthesis will be implanted using the Engager Transcatheter Delivery System. The bioprosthesis is delivered transapically on a catheter during a beating heart procedure.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Maastricht, Netherlands, 6229 GW
- Medtronic Bakken Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patient can be included if ALL of the following criteria are met:
- Patient with severe aortic valve stenosis requiring treatment;
- Patient is an acceptable candidate for elective treatment with the Medtronic Engager Transcatheter Aortic Valve Implantation System and in conformity with the local regulatory requirements;
- Patient is above the minimum age as required by local regulations to be participating in a clinical study;
- The patient has been informed of the nature of the study and has consented to participate, and has authorized the collection and release of his/her medical information by signing a consent form (Patient Informed Consent Form or Data Release Form).
Exclusion Criteria:
Patient will not be included if any of the following conditions exist:
- Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, Nitinol of contrast medium that cannot be adequately controlled with pre-medication;
- Intracardiac mass, thrombus, or vegetation;
- Aortic aneurysm;
- Sepsis or acute endocarditis;
- Bleeding diathesis, or coagulopathy;
- Cardiogenic shock, suspected cardiogenic shock;
- Unicuspid or bicuspid aortic valve;
- Pre-existing prosthetic heart valve in aortic position;
- Patient is currently enrolled in another investigational device or drug trial;
- Patients with life expectancy less than 12 months after TAVI.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
is to characterize the safety and clinical benefit of the Engager Transcatheter Aortic Valve Implantation System in a real world setting.
Time Frame: 12 months
|
The study objective is to characterize the safety and clinical benefit of the Engager Transcatheter Aortic Valve Implantation System in a real world setting. The primary endpoint of this study is all-cause mortality at 30 days or during index hospitalization. |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device success according to VARC2
Time Frame: 12 Month follow up
|
Absence of procedural mortality (all-cause mortality at discharge, 30 days or during index hospitalization), AND correct positioning of the Engager bioprosthesis in the proper anatomic location, AND Engager bioprosthesis performing as intended (no prosthesis-patient mismatch and mean aortic valve gradient < 20 mmHg or peak velocity < 3 m/s, AND no moderate or severe regurgitation). Composite early safety (at 30 days) according to VARC2. All-cause mortality at 6 months and 1 year; Cardiovascular mortality at 30 days, 6 months and 1 year; Incidence of TAVI-related complications at 30 days, 6 months and 1 year |
12 Month follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hendrik Treede, MD, Universitatsklinikum Hamburg
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAE00937
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Hospices Civils de LyonRecruiting
-
Edwards LifesciencesActive, not recruitingHeart Failure | Aortic Stenosis | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral StenosisUnited States, Canada, Poland
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
Clinical Trials on Engager Transcatheter Aortic Valve Implantation System
-
Medtronic Bakken Research CenterCompletedAortic Valve StenosisGermany, Israel, Belgium, Switzerland
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
Didier TCHETCHEAbbottNot yet recruitingBicuspid Aortic ValveFrance
-
University of PadovaFondazione GISE OnlusRecruiting
-
Xijing HospitalRecruitingAortic Valve Disease MixedChina
-
National University of Ireland, Galway, IrelandKarolinska University Hospital; Galway University Hospitals; Kerckhoff Heart... and other collaboratorsEnrolling by invitationAortic Stenosis | Transcatheter Aortic Valve Replacement | Bicuspid Aortic Valve | Transcatheter Aortic Valve ImplantationSweden, Ireland, Germany
-
Edwards LifesciencesCompletedSevere Aortic StenosisSpain, Italy, Canada, Belgium, Greece, Germany, Austria, United Kingdom, Finland, Denmark, France, Switzerland, Israel, Poland, South Africa, Czechia, Netherlands, Norway
-
Medical University of WarsawRecruitingAortic Valve Stenosis | Ventricular Outflow Obstruction, LeftPoland
-
Segeberger Kliniken GmbHCompleted
-
IRCCS Policlinico S. DonatoRecruiting